Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

BJ, Druker; F, Guilhot; SG, O'Brien; I, Gathmann; H, Kantarjian; N, Gattermann; MW, Deininger; RT, Silver; JM, Goldman; RM, Stone; F, Cervantes; A, Hochhaus; BL, Powell; JL, Gabrilove; P, Rousselot; J, Reiffers; JJ, Cornelissen; T, Hughes; H, Agis; T, Fischer; G, Verhoef; J, Shepherd; G, Saglio; A, Gratwohl; JL, Nielsen; JP, Radich; B, Simonsson; K, Taylor; M, Baccarani; C, So; L, Letvak; RA, Larson

doi:10.1056/nejmoa062867

Public

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Shared by NobleBlocks on Dec 1, 2006 • 12:00 AM UTC

Authors:

Druker BJ

Guilhot F

O'Brien SG

Abstract

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!